Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

1st December 2015 – Deal Facilitated between Children’s Medical Research Institute and Abbexa Ltd

Bio-Link has facilitated an Exclusive License, Supply and Distribution Agreement between Children’s Medical Research Institute and Abbexa Ltd (UK) for telomerase research reagents including a primary antibody and antigenic peptide for telomerase immunoprecipitation and telomerase high-expressing cell pellets. These novel telomerase research products represent powerful and important tools for superior purification of telomerase and more effective and accurate telomerase studies. This agreement makes these research products available to the academic research community for non-commercial research purposes. Click here for the full press release.


1st October 2015 – Bio-Link scouting for Inflammation and Fibrosis Drug Candidates

Bio-Link is currently scouting for in-licensing opportunities on behalf of a biopharmaceutical company client. We are interested in drug candidates at a preclinical lead (or further advanced) stage of development, with a primary focus on inflammation or fibrosis, for the lung, liver or kidney. Bio-Link Executive Director, Dr Christian Toouli, will be attending the AusBiotech 2015 Conference (Melbourne, 7 – 9th October) and would be pleased to meet with companies and institutions which are interested to potentially license or partner relevant drug candidates with a leading biopharma company.

bio-link square-linkedin150925

22nd September 2015 – Deal Facilitated between TransBio and DendroCyte

Bio-Link has facilitated a Convertible License Agreement between TransBio Ltd and DendroCyte BioTech Pty Ltd for the Development of Antibody Drugs Targeting CD83 to prevent graft versus host disease. The License Agreement is the culmination of a multi-year collaboration to discover and develop novel antibody therapeutics directed against CD83, a relatively new cell surface drug target with the potential to be developed as a safe and efficacious therapy for the prophylaxis and treatment of graft versus host disease and other adverse immune reactions such as transplant rejection. Click here for the full press release.


8th September 2015 – Children’s Cancer Institute and Sydney Children’s Hospital Network launch new joint initiative

Children’s Cancer Institute in conjunction with Sydney Children’s Hospital Network have launched an Australian first initiative to treat high-risk child cancer patients with patient specific tailored treatments. The program Zero Childhood Cancer is focused on detailed laboratory analysis on each child’s unique cancer cells to help identify which treatment is best suited for their specific cancer. The goal of this program is to achieve a 100% survival rate in childhood cancer in the future. Please see CCI’s press release here.


19th August 2015 – Bio-Link engaged by Realm Systems

Bio-Link has been engaged by Realm Systems to facilitate commercialisation of the Realm System, a precise and cost-effective, real-time technology for quantification of 3-dimensional joint loading. To read more about the Ream System technology, please click here.

realm system logo